Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and sustainability of pain therapy with human adipose-derived mesenchymal stem cell conditioned medium
jRCT1030220346Recruiting
- Sponsor
- Sawai Hospital
- Start
- Sep 2022
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of human adipose-derived mesenchymal stem cell conditioned medium in chronic pain, sponsored by Sawai Hospital. Primary endpoints: Effect of pain on daily life, Pain intensity (Numerical Rating Scale; NRS) and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
human adipose-derived mesenchymal stem cell conditioned medium
03
Conditions
chronic pain
Beyond the preview
Go deeper on jRCT1030220346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030220346.